2025 third_quarter Filing

S. 2296, the National Defense Authorization Act for 2026, Section 878, Country-of-Origin Disclosure Requirements for Generic Drugs Purchased by the Department of Defense, provisions relating to prohibiting the Department of Defense from procuring for resale any generic drug unless the seller of such generic drug discloses the country the drug was manufactured in and the country of origin of all active pharmaceutical ingredients and key starting materials; Federal policy relating to providing incentives and federal funding to strengthen capabilities for domestic manufacturing of generic drugs; and Federal policy relating to inspection of foreign generic drug manufacturing facilities.

Federal policy relating to addressing drug shortages and strengthening pharmaceutical supply chains through partnerships with North American and other allied countries; Federal policy relating to providing preferential federal direct and indirect purchasing treatment for domestic and North American manufactured pharmaceuticals; S. 43, Skinny Labels Big Savings Act, provisions relating to providing a safe harbor from infringement for a method of use patent relating to drugs or biological products; and HR 1483/S. 1302, The Increasing Transparency in Generic Drug Applications Act, provisions relating to the Food and Drug Administrations authority to share information about ingredients and deviations in inactive ingredient concentration with generic pharmaceutical product applicants.